Insulet Corp.

As of October 24, 2025, Insulet Corp. shows a mildly bullish trend with mixed technical signals, having outperformed the S&P 500 year-to-date and over the past year, but underperformed over the longer 3, 5, and 10-year periods.

As of October 24, 2025, Insulet Corp. shows a mildly bullish trend with mixed signals from technical indicators, having outperformed the S&P 500 year-to-date and over the past year, but underperformed over the last three and five years.

As of October 24, 2025, Insulet Corp. shows a mildly bullish trend with mixed signals from various indicators, having outperformed the S&P 500 year-to-date and over the past year, but lagging in longer-term performance.

As of October 3, 2025, Insulet Corp. shows a mildly bullish trend overall, with mixed signals from technical indicators across different time frames, having underperformed the S&P 500 recently but outperformed it year-to-date and over the past year.

As of October 3, 2025, Insulet Corp. shows a mildly bullish trend with mixed signals across different time frames, outperforming the S&P 500 year-to-date and over the past year, but underperforming over three and five years.

As of August 19, 2025, Insulet Corp. shows a bullish technical trend despite mixed signals from the RSI and KST, having outperformed the S&P 500 year-to-date and over the past year, but underperformed in the longer 3, 5, and 10-year periods.

As of August 7, 2025, Insulet Corp. is considered very expensive due to high valuation ratios compared to peers, despite recent short-term stock performance outperforming the S&P 500, indicating potential unsustainability in the long run.

As of March 11, 2025, Insulet Corp. is considered overvalued with a P/E ratio of 51, significantly higher than industry peers, indicating that investors may be paying too much for its growth potential despite a strong past year return of 50.74%.

As of June 10, 2025, the trend is mildly bullish due to supportive weekly MACD and KST indicators, though mixed signals from the monthly RSI and Dow Theory suggest some underlying weakness.

As of March 2022, the management team of Insulet Corp. includes Timothy Scannell (Independent Chairman), Shacey Petrovic (President and CEO), and several independent directors: Wayne Frederick, Sally Crawford, John Fallon, James Hollingshead, and Jessica Hopfield. They oversee the company's strategic direction and operations.

Insulet Corporation develops and sells the OmniPod Insulin Management System for insulin-dependent diabetes. As of March 2025, it reported net sales of $569 million and a market cap of approximately $21.42 billion.

As of Jun 18, Insulet Corp. has a market capitalization of $21.42 billion, with recent net sales of $2.20 billion and a net profit of $402.20 million.